C19orf42 Inhibitors
C19orf42 inhibitors encompass a diverse array of small molecules that target various signaling pathways, ultimately leading to the reduced functional activity of C19orf42 within cells. Compounds such as LY294002, and Wortmannin target the PI3K-Akt pathway, which is crucial for cell survival and proliferation. By inhibiting this pathway, these molecules create a cellular environmentthat is less supportive of the processes that C19orf42 may influence or regulate. Other inhibitors like PD98059 and U0126 disrupt the MAPK/ERK pathway, which is also essential for cell proliferation and differentiation. As C19orf42 may play a role in these cellular functions, attenuating the MAPK/ERK signaling can indirectly suppress the activity of C19orf42.
SB203580 and SP600125 target the stress-activated MAPK pathways, namely p38 and JNK, respectively. These pathways are important for the cellular response to stress and inflammation. If C19orf42 has a role in stress response, the inhibition of these pathways can lead to a decrease in its functional activity.Rapamycin, a well-known mTOR inhibitor, affects the mTOR pathway that regulates cell growth, proliferation, and survival. Through the inhibition of mTOR, Rapamycin can indirectly modulate the activity of C19orf42 by hindering the cellular conditions that favor growth and proliferation, which are possibly facilitated by C19orf42. Palbociclib, a CDK4/6 inhibitor, arrests the cell cycle and may thus inhibit the functional activity of C19orf42 if it is involved in cell cycle regulation. This inhibition can lead to a halt in cell division, which is an essential process for cancer cell proliferation and growth.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 prevents the activation of Akt, a kinase involved in the survival and proliferation of cells where C19orf42 is active. This inhibition can decrease the functional activity of C19orf42 by reducing the pro-survival signaling context in which it operates. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that blocks the phosphorylation and activation of Akt. By preventing Akt activation, Wortmannin can indirectly inhibit C19orf42 function due to the decreased survival signaling within the cell, which C19orf42 may rely on for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that works upstream of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can decrease ERK pathway signaling, potentially leading to reduced activity of C19orf42 if it is involved in cell cycle regulation or proliferation mediated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that impairs the MAPK/ERK signaling. C19orf42's function can be indirectly decreased when this pathway is inhibited, especially if C19orf42's activity is associated with signals that promote cell growth and division. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The inhibition of p38 MAPK can lead to reduced stress response signaling, potentially diminishing the functional activity of C19orf42 if it is involved in cellular responses to stress. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the stress-activated MAPK pathway. Inhibition of JNK signaling can lead to decreased cellular responses to stress or inflammation, potentially reducing C19orf42 activity if it is related to these cellular processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. Inhibition of mTOR by Rapamycin can indirectly decrease C19orf42 activity by creating an intracellular environment that is less supportive of the growth-related functions in which C19orf42 might be involved. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that can block cell cycle progression. If C19orf42 is involved in the regulation of the cell cycle, the inhibition of CDK4/6 by Palbociclib could indirectly inhibit the functional activity of C19orf42 by arresting the cell cycle. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasomal degradation pathway, Bortezomib can lead to the accumulation of misfolded or damaged proteins, potentially stressing the endoplasmic reticulum and indirectly influencing the functional activity of C19orf42 if it is involved in cellular stress responses. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytosolic calcium levels. Elevated cytosolic calcium can affect numerous signaling pathways and may indirectly inhibit C19orf42 function if it relies on calcium homeostasis. | ||||||